Background {#Sec1}
==========

Gestational diabetes mellitus (GDM) is a glucose intolerance condition that is first detected during pregnancy. Rapid societal transition from traditional foods and lifestyle to an obesogenic environment has exposed the Chinese people to high prevalence of GDM (8.1 to 19.7%) \[[@CR1]--[@CR3]\]. GDM caused by varying degrees of insulin resistance to placenta-derived hormones, and, which in turn, increases the maternal adipose tissue \[[@CR4]\]. Diagnosis of GDM is usually conducted with an abnormal oral glucose tolerance test (OGTT) at 24-28th week of gestation. Recently, there has been a controversy that skipping glucose on the first prenatal visit, could lead to correct GDM diagnosis \[[@CR5]\]. GDM has been reported to increase the risk of adverse fetal outcomes such as fetal macrosomia, and subsequent maternal consequences like metabolic syndrome and cardiovascular morbidity. However, early identification of identifying women at risk of GDM could aid in averting such risks, through early interventions \[[@CR6], [@CR7]\]. Various groups have attempted to develop models that can predict an abnormal OGTT occurrence at 24--28 weeks, based on risk factors identified in the first trimester. Methods such as scroring systems, glucose biochemical assays of, and glycosylated haemoglobin (HbA1c) levels have used in different populations with varying degrees of success \[[@CR8]--[@CR11]\]. Established risk factors of GDM include advanced maternal age, excessive weight gain during pregnancy, overweight or obesity, diabetes in first degree relatives, and giving birth to an infant with a macrosomia, etc \[[@CR12]\] However, clinical trials have shown that GDM can be relatively prevented through an intensive lifestyle modification implemented before 20 weeks of gestation \[[@CR13], [@CR14]\].

Different populations have different risk profiles for GDM. In Western countries, GDM mainly occurs in obese women (body mass index \[BMI\] \> 30 kg/m^2^) or women with increasing gestational weight gain \[[@CR15]--[@CR17]\]. In Asian countries however, it cuts across the women populations, making it difficult to pinpoint a possible cause. In the present study, our aim was to create a simple and implementable strategy for identifying GDM in pregnant Chinese women living in urban area.

Methods {#Sec2}
=======

Study design {#Sec3}
------------

This study conducted retrospectively from January 2015 to December 2015, in Shanghai. Dataset was obtained from the International Peace Maternity and Child Care Health Hospital (IPMCH) electronic medical record system. Eligible subjects who underwent first-trimester screening at the IPMCH were recruited in the study. The prospective cohort study was conducted in 2016. Demographic information of the subjects which included; last menstrual period, maternal age, gestational age, pre-pregnancy weight, current height, personal history, educational levels, parity, diabetes in first degree relatives, were obtained through a face-to-face interview questionnaire, at the first prenatal visit (9--13 weeks' gestation). Pre-pregnancy BMI was calculated by dividing the pre-pregnancy weight (kg) by the height squared (m^2^) and classified based on the Chinese criteria (underweight, \< 18.5 kg/m^2^; normal weight, \< 24.0 kg/m^2^; overweight, 24.0 kg/m^2^ ≤ BMI \< 28.0 kg/m^2^; obese, BMI ≥ 28.0 kg/m^2^) \[[@CR18]\]. Venous blood samples were obtained after overnight fasting for analysis of FPG and HbA1c, at the first visit to antenatal clinic.

GDM was diagnosed at 24--28 weeks of gestation according to the American Diabetes Association (ADA) criteria using abnormal plasma glucose values during the 2-h, 75-g OGTT. Abnormal values were defined according to ADA thresholds: a fasting level of 5.1 mmol/l or greater, a 1-h value of 10.0 mmol/l or greater, and, a 2-h value of 8.5 mmol/l or greater.

Exploratory cohort {#Sec4}
------------------

The hospital-based retrospective cohort study included 4774 women, who underwent their initial prenatal visit (9--13 gestational weeks) at the IPMCH in 2015. Women with pre-existing diabetes (FPG ≥ 7 mmol/L or HbA1c ≥ 6.5% during the first antenatal care or self-reported previous diabetes) (*n* = 54), multifetal pregnancies (*n* = 215) and missing data (*n* = 214 for no FPG tested, *n* = 178 for no OGTT performed, *n* = 157 for no records on family history) were excluded from the study. The remaining 3956 eligible women were used in further analysis.

External validation cohort {#Sec5}
--------------------------

Eligible participants, who attended prenatal care in the first trimester with single pregnancy, were selected and followed-up until GDM diagnosis in 2016, at the IPMCH. Women with pre-existing diabetes were excluded (*n* = 292). Therefore, the 6572 OGTT-tested women formed the dependent validation cohort of this study.

Development of an individualized prediction model {#Sec6}
-------------------------------------------------

Risk factors for GDM include advanced age, high pre-pregnancy BMI, diabetes in first degree relatives and high FPG in the first trimester. In the exploratory cohort, multiple logistic regression analysis was used to estimate the coefficients of each risk factor and mutually-adjusted odds ratio (OR) assigned for GDM. The continuous predictor variables such as age, BMI and FPG were found to be linear with log odds of the outcomes. To provide clinicians with a quantitative tool to visually predict individual probability of GDM, we developed a nomogram based on multivariable logistic analysis in the exploratory cohort. To further quantify the accuracy of the prediction models in discriminating subjects with GDM from subjects without, a receiver operating characteristic (ROC) curve was plotted, and the area under the curve (AUC) was calculated. Calibration was evaluated with the calibration curve. Ideally, the closer the dots are to the 45 degree line the better the model. Internal validation was initially analyzed by bootstrapping with 1000 random samples drawn with replacement. The ROC curve and calibration plot for recalibrated train model were extended to internal and external validation datasets. Decision curve analysis was used to determine the clinical usefulness of the nomogram by quantifying the net benefits at different threshold probabilities in the validation datasets. Spatially mapped t-distributed stochastic neighbor embedding (t-SNE) was used to distinguish non-GDM from GDM, i.e. the ability to screen for a true negative group.

Statistical analysis {#Sec7}
--------------------

Analyses were performed using SPSS version 23.0 (SPSS, Inc., Chicago, IL) and R statistical software version 3.6.1 (packages rms, rmda, and Rtsne). Continuous variables were presented as the means with standard deviations, while categorical data were expressed as counts and percentages. Levene's test was used to determine the homogeneity of the variances, and, Kolmogorov-Smirnov was used to assess the normal distribution. Summary statistics between both groups were compared using either unpaired Student's t-test or Mann-Whitney tests for continuous data, and chi-squared tests for categorical data. Crude and mutually adjusted OR with 95% confidence interval (CI) for associations between baseline risk factors and GDM were estimated using the logistical regression model. Nomogram and calibration curve were performed with the "rms" package. The package "rmda" provided tools for evaluating the value of using a risk prediction instrument in deciding treatment or intervention. The "Rtsne" package was used to assess the screening ability based on construction of a low dimensional embedding of high-dimensional data, distances or similarities. A *p*-value of \< 0.05 was considered to indicate statistical significance.

Results {#Sec8}
=======

Baseline characteristics for two cohorts {#Sec9}
----------------------------------------

In the retrospective cohort of 3956 women, 662 developed GDM (16.7% incidence). The median ± SD pregnancy week for the first prenatal visit was 10.2 ± 3.5. Their mean age was 30.61 years, mean pre-pregnancy BMI (21.45 kg/m^2^), median FPG value (4.45 mmol/L), and presence of diabetes in first degree relatives (27.4%). In the external validation cohort of 6572 women, 739 developed GDM (11.2% incidence). The median ± SD pregnancy week for the first prenatal visit was 10.4 ± 3.3. Their mean age was 30.84 years, mean pre-pregnancy BMI was (21.20 kg/m^2^), median FPG (4.40 mmol/L), and presence of diabetes in first degree relatives (16.5%). Comparison of baseline characteristics between GDM and non-GDM in the two cohorts is shown in Table [1](#Tab1){ref-type="table"}. In both cohorts, women who developed GDM had a relatively higher prevalence of family history of diabetes, advanced age, increased pre-pregnancy BMI, FPG, and multipara. However, education levels of the two groups was similar (*p* \> 0.05), as was fetal sex. Significant differences were observed in the clinical characteristics between the exploratory dataset and the validation dataset (*p* = 0.04 for age, 0.24 for BMI, 0.001 for family history and 0.03 for FPG). However, the key difference between the two cohorts was in the GDM incidence (16.7% v 11.2%, *p* \< 0.001). Even though many factors could contribute to this difference in incidence, we attributed the scenario to an antenatal education program that teaching pregnant women to manage their diets and weight during pregnancy. Table 1General characteristics of women with normal glucose tolerance and those who developed GDMRetrospective cohort (*n* = 3956)Prospective cohort (*n* = 6572)GDM (*n* = 662)Non-GDM (*n* = 3294)*P*GDM (*n* = 739)Non-GDM (*n* = 5833)*P*Age, years31.73 ± 3.7430.39 ± 3.52\< 0.00132.24 ± 3.9530.66 ± 3.69\< 0.001Pre-BMI, kg/m^2^22.63 ± 3.4321.21 ± 2.71\< 0.00122.45 ± 3.3721.04 ± 2.69\< 0.001Categorized pre-BMI\< 0.001\< 0.001 Underweight, n (%)47 (7.10)365 (11.80)61 (9.06)812 (14.53) Normal weight, n (%)436 (65.86)2513 (76.29)434 (64.49)4070 (72.85) Overweight, n (%)128 (19.33)348 (10.56)127 (18.87)557 (9.97) Obese, n (%)51 (7.70)68 (2.06)51 (7.58)115 (2.06)FH, n (%)\< 0.001\< 0.001 No403 (60.90)2468 (74.90)530 (71.70)4960 (85.00) Yes259 (39.10)826 (25.10)209 (28.30)873 (15.00)FPG, mmol/L4.61 ± 0.454.42 ± 0.38\< 0.0014.59 ± 0.524.38 ± 0.38\< 0.001Parity, n (%)\< 0.001\< 0.001 Nullipara498 (75.23)2697 (81.88)507 (68.61)4337 (74.35) Primi or multipara164 (24.77)597 (18.12)232 (31.39)1496 (25.65)Educational levels, n (%)0.3140.074 Primary education194 (29.31)867 (26.32)82 (11.10)519 (8.89) Bachelor362 (54.68)1825 (55.40)529 (71.58)4173 (71.54) Master99 (14.95)557 (16.91)111 (15.02)1011 (17.33) Doctor7 (1.06)45 (1.37)16 (2.30)130 (2.23)Fetal sex, n (%)0.0950.399 Male332 (50.15)1535 (46.59)345 (46.68)2815 (48.26) Female330 (49.85)1759 (53.40)394 (53.32)3018 (51.74)Data are *n* (%), mean ± SD or median ± SD*p* values for differences between two groups were obtained by ANOVA or χ2 test*GDM* gestational diabetes mellitus; *pre-BMI* pre-pregnancy body mass index, *FH* family history; *FPG* fasting plasma glucose

Logistic regression results {#Sec10}
---------------------------

Table [2](#Tab2){ref-type="table"} shows the incidence of risk factors for GDM with OR from a multiple logistic regression model in the exploratory cohort (*n* = 3956). Increasing age, pre-pregnancy BMI, FPG and a family history of diabetes were confirmed as independent risks for GDM. Table 2GDM risk factors according to disease status and Odds Ratios (ORs) in two cohortsVariablesExploratory cohort (*n* = 3956)External validation cohort (*n* = 6572)Crude OR (95% CI)Adjusted OR (95%CI)*P*Crude OR (95% CI)Adjusted OR (95%CI)*P*Age, years1.11 (1.08--1.14)1.09 (1.06--1.11)\< 0.00011.12 (1.09--1.14)1.01 (1.07--1.12)\< 0.0001Pre-BMI, kg/m^2^1.18 (1.14--1.22)1.13 (1.09--1.17)\< 0.00011.17 (1.13--1.21)1.11 (1.08--1.15)\< 0.0001Family history1.89 (1.57--2.26)1.64 (1.36--1.98)\< 0.00012.19 (1.81--2.66)1.93 (1.58--2.35)\< 0.0001FPG3.28 (2.62--4.11)2.60 (2.07--3.27)\< 0.00013.47 (2.77--4.34)2.77 (2.20--3.48)\< 0.0001parity1.49 (1.22--1.81)1.14 (0.91--1.43)0.2661.32 (1.12--1.56)0.89 (0.74--1.07)0.216Based on multiple logistic regression models adjusted mutually*OR* odds ratio, *pre-BMI* pre-pregnancy body mass index, *FPG* fasting plasma glucose
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Development of GDM-predicting nomogram {#Sec11}
--------------------------------------

A nomogram incorporating age, pre-pregnancy BMI, FPG in the first trimester and a family history of diabetes was developed and presented as shown in Fig. [1](#Fig1){ref-type="fig"}. Fig. 1Nomogram to estimate the risk of GDM. Each predictor is assigned a score on each axis. Compute the sum of points for all predictors and denote this value as the total points. The corresponding "risk of GDM" of "total point" was converted to a predicted probability of GDM

Discrimination results {#Sec12}
----------------------

We depicted ROC curves with 3956 subjects from the exploratory cohort. The AUC for the prediction nomogram was 0.69 \[95% CI:0.67--0.72, *p* \< 0.0001\], while the corrected c-index was 0.69 in the internal bootstrap validation. Applying the exploratory set estimates to the validation set yielded a similar AUC of 0.70 \[95% CI: 0.68--0.72, *p* \< 0.0001\].

Calibration results {#Sec13}
-------------------

The probability of GDM occurrence in the exploratory and validation cohorts was accurately predicted form the calibration curve (Fig. [2](#Fig2){ref-type="fig"}a-c). Fig. 2Calibration results. Nomogram-predicted probability of GDM is plotted on the x-axis; actual probability of GDM is plotted on the y-axis. The ideal calibration line means an intercept of 0 and a slope of 1 for the calibration plot. Exploratory cohort (**a**); Internal validation cohort (**b**); External validation cohort (**c**)

Clinical use {#Sec14}
------------

For predicted probability thresholds between 0.05 and 0.78, our model showed a positive net benefit, without increasing the number of false positives (Fig. [3](#Fig3){ref-type="fig"}). Fig. 3Decision curve analysis for gestational diabetes mellitus. Solid black line = net benefit when no one is at risk for gestational diabetes mellitus (GDM); grey line = net benefit when all are at risk for GDM. The y-axis measures the net benefit. The red line represents the nomogram. The decision curve showed that if the threshold probability is between 0.05--0.78, using the nomogram in the current study to predict GDM adds more benefit than the intervention-all-patients scheme or the intervention-none scheme

Screening ability {#Sec15}
-----------------

To assess the suitability of linking the structure revealed by t-SNE to clinical outcome, and thereby discriminating subpopulations, we converted the t-SNE space to a\*b color space. In the resulting t-SNE image obtained by density-based analysis, each pixel was colored according to its property (Orange for GDM and blue for non-GDM). In both cohorts (Fig. [4](#Fig4){ref-type="fig"}a-b), the distinct regions of GDM and non-GDM outlined by t-SNE were separated, hence generating transitional boundaries that could be highlighted by two different colors. This demonstrated the ability to distinguish GDM from non-GDM women. Fig. 4Screening ability of this model. Orange color represented for GDM women, blue point represented for non-GDM women. t-SNE result showed the majority of non-GDM women were separated from GDM women by an obvious boundary in the retrospective cohort (**a**). t-SNE showed the similar result in the prospective cohort (**b**). GDM: gestational diabetes mellitus

Discussion {#Sec16}
==========

In this study, we developed and validated a diagnostic nomogram for the prediction of GDM. The nomogram incorporated four risk factors including age, pre-pregnancy BMI, FPG in the first trimester and history of diabetes in first-degree relatives. Earlier in pregnancy, the nomogram successfully stratified the women according to their risk of developing GDM. Its prediction was supported by the AUC (0.69 and 0.70 for the exploratory and validation cohorts, respectively) and the calibration curve. Incorporation of the easily accessible risk factors into our nomogram enhanced the process individualized prediction of GDM.

Heterogeneity of physiological processes underlying hyperglycemia has been reported among women with GDM \[[@CR19]\]. Therefore, an integrated approach that combines multiple risk indicators, could accurately predict the women who should be screened further for GDM. FPG widely used as a screening test for GDM through detection of preexisting diabetes (FPG ≥ 7 mmol/L) in the first trimester. High pre-pregnancy BMI or normal upper range of FPG was associated with insulin sensitivity defect, condition which could be involved in the onset of GDM \[[@CR5], [@CR19]\]. In China, it is traditional for women to increase their calorie consumption and sedentary habit from the onset of pregnancy though this is clearly responsible for increasing diabetogenic burden in high risk women \[[@CR20]\]. It should be emphasized that our study was conducted at a time when early identification and targeted interventions are available for those women .

Various first-trimester prediction models for GDM have been proposed \[[@CR21]--[@CR23]\]. However, these models are not commonly used in routine clinical care. First, this could be partly attributed to poor external validation of these models since clinical use was not considered during their development. Secondly, indicators, such as high molecular weight adiponectin, omentin-1 and interleukin-6, yield a high AUC, but also increase the psychological and economic burden \[[@CR24]\]. We generated a decision curve analysis to quantify the clinical usefulness, and a key finding was that a single probability threshold could be used both to categorize patients as positive or negative, and to weight false positive and false negative classifications \[[@CR25]\]. In our model, the use of a 0.05--0.78 threshold to identify individuals with high risk of GDM always had a positive net benefit.

HbA1c showed a high sensitivity but insufficient power to diagnose GDM \[[@CR26]\]. Sumaiya Adam et al. \[[@CR22]\] reported that adding a HbA1c did not significantly improve the predictive value of prediction model for GDM. In addition, HbA1c levels vary with gestational hemodilution, hemoglobin disease, and/or anemia. Therefore, we did not consider it as risk factor, in our model.

To assess its predictive performance, we validated our model both internally and externally. Its main advantage is the ability to integrate information that is routinely obtained at the first antenatal visit into a graphical nomogram. Heterogeneity was observed between the demographic characteristics of the train set and external validation set. Therefore, heterogeneity could be used to reflect and evaluate the applicability of the model in external population, and improve the overall application value of the model. Inclusion of both first and second degree relatives with diabetes in the retrospective cohort could have over-estimated the contribution of family history with some measurement bias. Hence, in the prospective cohort we only considered the first degree relatives with diabetes.

This study had the following limitations. First, our study was based on the hospital cohort, and the homogeneity of the cohort increased the internal validity while wakening the confidence of representation of the Chinese population. A prospective, multicenter, trial could therefore be required to test our prediction model. Second, we did not incorporate excessive gestational weight gain though it was a key factor in GDM development. Third, the sample size of the retrospective cohort was smaller than the prospective cohort, due to some women returning to their home towns to deliver, while others refused to participate in the study in 2015. However, the final sample size (*n* = 3956) was sufficient for establishing the prediction model, indicating that these attritional features did not result in a type I error. Finally, the AUC value in our model did not show high prediction accuracy. However, since AUC metric solely focuses on the predictive accuracy. It cannot be used to identify a preferable model. A model with a greater specificity but slightly lower sensitivity would have a higher AUC, but would be a poorer choice for clinical use. We therefore further used Decision-analytic methods, which incorporated our results and theory to determine the worthiness of a model or alternatives.

Conclusions {#Sec17}
===========

In conclusion, we have developed a simple nomogram for pregnant Chinese women that can be used to estimate the probability of developing GDM at the first antenatal visit. This prediction model could identify women at risk for GDM early in pregnancy, allowing for timely intervention to improve maternal outcome. However, further studies should be carried out in other cities to improve the prediction accuracy of GDM risk in the Chinese, or even Asian populations.
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